Key statistics
Previous close$15.60
Open$15.26
Day high$15.64
Day low$15.09
52-week high$23.75
52-week low$10.95
Market cap1.14B
Volume940.14K
Average volume1.40M
P/E ratio-10.87
Forward P/E—
EPS-1.41
Dividend yield0.00%
Market context
Why it moved
Schrodinger (SDGR) edged lower as sentiment remained subdued following the CFO's sale of shares, even though the transaction was a pre-planned, non-discretionary sale under a Rule 10b5-1 plan to cover tax withholding on vested RSUs, combined with the stock's ongoing weakness amid a challenging period for the company.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026Schrödinger shares fell roughly 4% on Wednesday, pressured by a broad software sector rout ignited by IBM's historic earnings warning. IBM's preliminary Q2 results — which sent the stock down 25%, its worst day in 115 years — revealed customers were diverting IT budgets away from software toward AI infrastructure hardware, stoking fears of a structural headwind across the sector. Despite the sector turbulence, BMO Capital analyst Evan Seigerman reaffirmed a Buy rating on Schrödinger with a $24 price target, signaling some analyst conviction in the company's differentiated computational drug discovery platform even as peer software names like ServiceNow, Salesforce, and Adobe also sold off sharply.-4.118
July 16, 2026Schrödinger edged up modestly in regular trading, outperforming most software peers, even as IBM's historic 25% single-day collapse sent shockwaves through the broader software sector. IBM's preliminary Q2 earnings miss—driven by clients reprioritizing capex toward AI hardware and memory over software—sparked a sector-wide selloff in names like ServiceNow, Workday, and Salesforce. For Schrödinger, whose computational drug discovery platform occupies a niche intersection of AI and life sciences software, investors appear to be distinguishing it from enterprise software broadly, though the macro headwind of AI spending crowding out software budgets remains a key risk to monitor.0.8679
July 15, 2026Schrödinger shares declined amid a broad software sector selloff triggered by IBM's historic earnings warning, which revealed enterprise clients are cutting software budgets to prioritize hardware and memory purchases ahead of expected price increases. IBM's stock suffered its worst single-day drop in history — falling over 25% — and dragged down the iShares Expanded Tech-Software Sector ETF (IGV) by roughly 2%, with peers like Salesforce and Microsoft also lower. The IBM-driven 'SaaSpocalypse' narrative weighed on the software application space broadly, as investors reassessed AI budget concentration trends highlighted by Citi, which noted spending is consolidating among a narrow set of data infrastructure platforms rather than spreading across the software sector.-1.7063
July 14, 2026Schrödinger closed modestly lower, slipping alongside broader software sector pressure as geopolitical tensions between the U.S. and Iran rattled equity markets, pushing oil higher and weighing on tech stocks. The company's "Hold" consensus rating and an average analyst price target of $20.25—representing roughly 23% upside—reflect a divided Wall Street, with Citi's broader Q2 software preview highlighting a widening AI spending divergence that could challenge Schrödinger's positioning as enterprise AI budgets concentrate on data infrastructure platforms rather than specialized application software.-0.4851
July 11, 2026Schrödinger shares declined amid a challenging backdrop for software and tech names, as the broader sector faced headwinds from geopolitical tensions surrounding renewed U.S.-Iran military exchanges and concerns that AI could commoditize software platforms. A recent Seeking Alpha analysis characterized the company as 'surviving, if not thriving' in the competitive AI drug discovery field, underscoring investor uncertainty about whether its physics-based computational platform can maintain an edge as AI tools proliferate across pharma R&D. The XLK technology ETF also closed lower on the day, reflecting broader sector pressure, even as the S&P 500 edged modestly higher near its 52-week high.-1.7868
July 10, 2026Schrödinger shares rallied as software stocks rebounded amid a broader rotation away from semiconductors and into software names, with chip stocks declining over 12% recently as the AI trade shifts. A fresh Seeking Alpha analysis highlighted SDGR's physics-based computational platform and pharma partnerships as resilient assets in the competitive AI drug discovery field. The gains came despite ongoing macro headwinds—escalating U.S.-Iran tensions rattled energy markets and revived inflation fears—suggesting sector rotation dynamics were a primary tailwind for the software-focused biotech tools company.4.3505
July 9, 2026Schrödinger declined as broader risk-off sentiment swept through technology and growth stocks, driven by Trump declaring the U.S.-Iran ceasefire 'over,' sending oil prices surging 5%+ and stoking renewed inflation fears. A Seeking Alpha analysis published today characterized the company as a 'Hold,' citing the high-risk, hit-or-miss nature of AI-driven drug discovery — underscoring persistent investor uncertainty about when Schrödinger's computational chemistry platform will translate into durable revenue growth. The selloff in AI and software names weighed on the broader tech sector, while rising Treasury yields and Fed minutes scrutiny added pressure to high-multiple growth stocks like SDGR.-2.4257
July 8, 2026Schrödinger shares declined amid a broad tech and AI-linked selloff triggered by Samsung's paradoxical 'sell-the-news' reaction to blowout Q2 earnings, which dragged down chip stocks and weighed on high-multiple growth names across software. The broader software sector continues to navigate the 'SaaSpocalypse' narrative — fears that AI agents will erode seat-based SaaS demand — with the IGV software ETF down ~10.5% YTD even as fundamentals from peers like Salesforce and ServiceNow remain resilient, keeping sentiment fragile for names like Schrödinger that sit at the intersection of AI and enterprise software.-3
Simply Wall Street · June 23, 2026How Investors May Respond To Schrödinger (SDGR) Hosted Model Transition And Updated 2026 Targets↗Moomoo · May 25, 2026Schrodinger | 10-Q: Q1 2026 Earnings Report↗Business Wire · May 5, 2026Schrödinger Reports First Quarter 2026 Financial Results↗Investing.com · May 5, 2026Earnings call transcript: Schrödinger misses EPS but beats revenue in Q1 2026↗ Benzinga · July 1, 2026Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AIBenzinga · May 20, 2026Schrodinger Reaffirms FY And Q2 2026 Financial And Operational GuidanceBenzinga · May 14, 2026Morgan Stanley Maintains Equal-Weight on Schrodinger, Lowers Price Target to $17Benzinga · May 5, 2026Schrodinger Affirms FY2026 Sales Guidance of $273.000M-$293.000M vs $252.752M EstMt Newswire · May 5, 2026Earnings Flash (SDGR) Schrodinger, Inc. Reports Q1 Revenue $58.6M, vs. FactSet Est of $47.6MBenzinga · May 5, 2026Schrodinger Q1 Adj. EPS $(0.63), Inline, Sales $58.587M Beat $48.002M EstimateBenzinga · April 13, 2026Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $20Benzinga · March 17, 2026UBS Maintains Neutral on Schrodinger, Lowers Price Target to $13
Peers
SPXS&P 500SPX · $7,457.69-1.01%
CERCertara, Inc.CERT · $6.93-4.81%
RXRRecursion Pharmaceuticals, Inc.RXRX · $2.95-2.48%
SLPSimulations Plus, Inc.SLP · $18.230.00%
PHRPhreesia, Inc.PHR · $10.71-1.65%
VEEVeeva Systems Inc.VEEV · $195.38-1.01%
TEMTempus AI, Inc.TEM · $52.47-2.09%
HQYHealthEquity, Inc.HQY · $97.67-1.03%
TDOTeladoc Health, Inc.TDOC · $9.43-0.42%
GDRGoodRx Holdings, Inc.GDRX · $3.14+0.64%
EVHEvolent Health, Inc.EVH · $5.81+2.47%
CGECompugen Ltd.CGEN · $2.37+1.72%
